跳至主導覽
跳至搜尋
跳過主要內容
國立中央大學 首頁
說明與常見問題
English
中文
首頁
人才檔案
研究單位
研究計畫
研究成果
資料集
榮譽/獲獎
學術活動
新聞/媒體
影響
按專業知識、姓名或所屬機構搜尋
Machine-learning-based predictions of direct-acting antiviral therapy duration for patients with hepatitis C
Theodore C. Feldman, Jules L. Dienstag, Kenneth D. Mandl, Yi Ju Tseng
資訊管理學系
研究成果
:
雜誌貢獻
›
期刊論文
›
同行評審
3
引文 斯高帕斯(Scopus)
總覽
指紋
指紋
深入研究「Machine-learning-based predictions of direct-acting antiviral therapy duration for patients with hepatitis C」主題。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Keyphrases
Hepatitis C
100%
Machine Learning Prediction
100%
Direct-acting Antiviral Therapy
100%
Duration of Therapy
100%
Direct-acting Antiviral Treatment
100%
Direct-acting Antivirals
75%
Quality of Life
50%
Machine Learning Models
50%
Patient Characteristics
50%
Decompensated Cirrhosis
50%
United States
25%
Treatment Duration
25%
Area under the Receiver Operating Characteristic Curve
25%
Predictive Models
25%
Type 2 Diabetes Mellitus (T2DM)
25%
Comorbidity
25%
XGBoost
25%
Extended Treatment
25%
Claims Data
25%
Prolonged Treatment
25%
Lifetime Enhancement
25%
Sofosbuvir
25%
Managed Care
25%
Antiviral Resistance
25%
Comorbidity Burden
25%
Ledipasvir
25%
Prolonged Course
25%
Chronic Infection
25%
Blood-borne Pathogens
25%
Multiple Comorbidities
25%
Care Plan
25%
Diabetes Status
25%
Nursing and Health Professions
Hepatitis C
100%
Treatment Duration
100%
Antiviral Therapy
100%
Antivirus Agent
50%
Comorbidity
37%
Quality of Life
25%
Area under the Curve
25%
Infection
12%
Receiver Operating Characteristic
12%
Drug Therapy
12%
Practice Guideline
12%
Non Insulin Dependent Diabetes Mellitus
12%
Decompensated Liver Cirrhosis
12%
Ledipasvir Plus Sofosbuvir
12%
Liver Cirrhosis
12%
Medicine and Dentistry
Hepatitis C
100%
Antiviral Therapy
100%
Treatment Duration
100%
Antivirus Agent
37%
Quality of Life
25%
Patient Characteristics
25%
Health Care Cost
12%
Infection
12%
Pathogen
12%
Maturity Onset Diabetes of the Young
12%
Drug Therapy
12%
Retrospective Study
12%
Ledipasvir Plus Sofosbuvir
12%
Decompensated Liver Cirrhosis
12%
Liver Cirrhosis
12%
Antiviral Resistance
12%
Pharmacology, Toxicology and Pharmaceutical Science
Antivirus Agent
100%
Antiviral Therapy
100%
Hepatitis C
100%
Comorbidity
37%
Infection
12%
Non Insulin Dependent Diabetes Mellitus
12%
Liver Cirrhosis
12%
Retrospective Study
12%
Ledipasvir Plus Sofosbuvir
12%
Bloodborne Bacterium
12%
Decompensated Liver Cirrhosis
12%
Neuroscience
Antivirals
100%
Hepatitis C
100%
Ledipasvir Plus Sofosbuvir
8%